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Jyolsna Agnes Jose aAbstractPurpose: Current treatment for glaucoma includes beta-blockers and prostaglandin analogues which have their own disadvan-
tages. Thus a need exists for new ocular hypotensive agents that are more efficacious and have fewer side effects. Therefore, for-
skolin eye drops 1%, through herbal product; a clinical trial was carried out for the safety and efficacy in the treatment of open
angle glaucoma.
Methods: Ninety adult male/female patients of 18–60 years of age, of either sex, suffering from open angle glaucoma with an
intraocular pressure (IOP) of more than 24 mm Hg were enrolled in the study. Patients were advised to instill 2 drops thrice a
day (8:00 h, 14:00 h and 20:00 h) and tonometric readings were recorded on baseline visit and on Visit 2, i.e. end of 1st week,
Visit 3–2nd week, Visit 4–3rd week, and Visit 5–4th week. The reduction in IOP across each time point from untreated baseline
visit and reduction in IOP across various study visits were measured.
Results: The mean (95% CI) difference in reduction in IOP was 4.5 mm Hg (P < 0.05) in the right eye and was 5.4 mm Hg (p < 0.05)
in the left eye from baseline visit (Visit 1) to final visit (Visit 5).
Conclusions: Forskolin 1% eye drops can be a safe alternative to beta blockers in glaucoma patients having concomitant asthma.
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Glaucoma is a leading cause of blindness and vision loss.1
It is the most frequent cause of irreversible blindness world-
wide and the second most frequent cause of irreversible
blindness worldwide after cataract2 and therefore improved
methods of screening and therapy for glaucoma are urgently
needed.3 Persistent high intraocular pressure which
characterizes this condition, can lead to worsening of the dis-
ease.4 Currently, there are many drugs available for loweringIOP acting through various mechanisms; however, for ade-
quate control of the IOP along with the minimal side effects,
new drugs are the need of the hour.
Coleus forskohlii is an aromatic herb growing all over India
from the Himalayas to Southern India. From the roots of this
plant is extracted forskolin and it has been studied over the
last three decades as a very interesting biological tool.
Current treatment for glaucoma includes beta-blockers
and prostaglandin analogues. Beta blockers show systemic
side effects that affect the heart and lungs while thee:
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198 M. Majeed et al.increased iris pigmentation with prostaglandin analogues is a
disadvantage.5 A need exists for new ocular hypotensive
agents that are more efficacious and have fewer side effects
than those used currently. Results from previous pilot
exploratory studies indicate that forskolin eye drops may
improve the overall symptoms of glaucoma. The current
study on forskolin 1% eye drops, confirms the efficacy of
the product over a large sample size, and could be an
alternative in asthmatic patients having glaucoma, who are
contradicted to use conventional beta blockers.Figure 1. Figures indicate mean decrease in IOP (mm Hg) at baseline visit
across various time intervals i.e. 0 h, 0.5 h, 1 h, 2 h, 3 h, 4 h, 5 h and
6 h – postinstillation of forskolin eye drops (1%) [Right & Left Eye]. After
administration of first dose (two drops) of forskolin 1% eye drops,
decrease in IOP was observed at the first reading (30 min. after
administration), reached statistical significance from 1 h onward and
IOP continued to drop till 4 h and then remained at plateau for next 2 h.
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Figure 2. Figure presents effect of treatment on IOP at every follow up
visit. It represents the mean decrease in IOP at the first time interval of
every follow up visit i.e. Visits 2–5. There was a considerable decrease in
the IOP at the first follow-up visit, and reached a statistical significance
from second follow up visit (Visit 3) which was maintained till the last study
visit.Materials and methods
The clinical study was approved by the Drug Controller
General of India (DCGI), New Delhi and the trial was con-
ducted in accordance with the Good Clinical Practice guide-
lines and by adhering to all the tenets of the Declaration of
Helsinki. Forskolin 1% eye drops study material was supplied
by the manufacturer Sami Labs Limited, India, This trial
involved 90 adult patients screened and enrolled at three
clinical centers across India. With respective Institutional
Ethics Committee approvals, patients diagnosed with open
angle glaucoma with an IOP of more than 24 mm/Hg, who
had not received miotic therapy for 24 h and systemic
therapy for at least 4 days, were enrolled. The nature and
purpose of the trial were explained in detail to all participants
and their informed consent was obtained, in writing.
Subjects who met all the Inclusion Criteria but none of the
exclusion criteria were selected for the current study:
Inclusion Criteria – (a) Adult male or female subjects having
primary open angle glaucoma, (b) Glaucoma with IOP of
more than 24 mm Hg, (c) No miotic or other therapy 24 h
before, (d) Off systemic therapy for glaucoma for at least four
days, (e) Informed consent given. Exclusion Criteria – (a)
Subjects with conditions such as secondary or closed angle
glaucoma, bronchial asthma, chronic obstructive pulmonary
disease, uncompensated cardiac failure, pregnancy, sinus
bradycardia or 2nd or 3rd degree atrio-ventricular block were
excluded from the trial, (b) Subjects, who have taken any
anti-inflammatory ophthalmic dose in the past 3 months,
were barred. (c) Subjects having concurrent drug intake
e.g. b blockers and diamox were also excluded. (d)
Pregnancy was also exclusion for this trial. A washout period
of 4 weeks has been maintained from the day of screening as
per international recommendations.6
The enrolled patients were assessed for demographic,
complete clinical and physical examination including severity
of eye symptoms. Concomitant treatment was also noted
(see Table 1). Patients underwent an IOP recording by a
validated Goldmann applanation tonometry using a mean
of 2 readings at 0 h before study medication was instilled in
the affected eye/eyes. Readings were recorded for the right
and left eye and both the eyes were analyzed as separate
entries. After administering 2 drops of forskolin 1% in the
affected eye, tonometric readings were subsequently taken
at 0.5, 1, 2, 3, 4, 5 and 6 h. For these IOP measurements,
the subjects were to relax 15 min before, and two readings
were taken in supine position. These readings were recorded
in duplicate, and a mean of two readings was considered for
statistical analysis.
The study duration was for 4 weeks. There were 4 follow
up visits besides baseline visit (Week 2–Week 5).Throughout the study duration, patients were to instill 2
drops of study medication, 3 times a day (8:00 h, 14:00 h
and 20:00 h). Patients were advised not to instill the med-
ication on the morning of the follow up visits, during which,
the signs, symptoms and adverse effects were recorded on
the Case Record Form. On the day of visit to the clinical site,
after administering 2 drops of forskolin 1% in the affected
eye, tonometric readings were subsequently taken at 0.5, 1,
2, 3, 4, 5 and 6 h. A qualified personnel who was independent
of the study was designated by the Principal Investigator for
IOP measurements to avoid potential bias. Tonometric read-
ings were recorded in duplicates and a mean of two readings
was considered at the respective time intervals. The same
process was followed during all the subsequent visits.
Physical and clinical examination, assessment of adverse
events and concomitant medications were recorded on all
the follow up visits as well. Adverse events were evaluated
by asking patients a general query about their state of health
since their respective previous or earlier study visits.Results
Across three clinical centers, ninety subjects (53 males and
37 females) participated in this trial and their mean age was
51.6 ± 11.9 years, and weight 66.0 ± 13.7 kg. Other patient
demographic characteristics are depicted in Table 2, as mean
Table 1. Schedule of Events.
Procedures Screening Baseline Visit Visit 2 Visit 3 Visit 4 Visit 5
Day 0 Day 7 Day 14 Day 21 Day 28
Signed informed consent X
Inclusion and exclusion criteria X
Demographics X
Medical history and physical examination X X X X X X
Tonometric readings X X X X X X
Concomitant medications X X X X X
Adverse events X X X X X
Table 2. Patient demographic characteristics.
N (sample size) 90
Age (Mean ± S.D.) 51.6 ± 11.9
Male (n) 53 (58.9%)
Female (n) 37 (41.1%)
Weight (kgs) (Mean ± S.D.) 66.0 ± 13.7
SBP (mm Hg) 128.3 ± 13.5
DBP(mm Hg) 82.7 ± 9.4
Heart rate (beats/min) 78.8 ± 7.0
Forskolin – A natural drug for open angle glaucoma 199values. All the 90 subjects enrolled in the trial completed the
study and no serious adverse effects were recorded.
However, 22 patients reported mild irritation of no clinical
significance on instillation, at baseline visit.
Statistical analysis using the SPSS statistical software with
the paired t-test at 95% confidence interval (C.I) and 0.05
level of significance showed an effect of forskolin 1% eye
drops (p < 0.05) on the IOP. Data are present as
mean ± SEM, unless otherwise indicated.
Safety
Few subjects reported adverse events such as redness,
burning and itching, which were of mild and transient nature
lasting for few seconds only and did not lead to withdrawal
from the study.
Efficacy
There was a decrease from baseline in the IOP at the first
follow-up visit, which was maintained till the end of the study.
At a 95% C.I, the mean difference in reduction in IOP, mea-
sured in mm Hg, was 4.5 (p < 0.05) in the right eye and 5.4
(p < 0.05) in the left eye between baseline visit (Visit 1) and
final visits (Visit 5) (see Figs. 1 and 2).Discussion
The estimated prevalence of glaucoma for India is 11.9
million.7 As of 2010, there were 44.7 million people in the
world with open angle glaucoma.8 IOP is a major risk factor
for the development of glaucoma.9 In open-angle glaucoma,
the typical progression from normal vision to complete blind-
ness takes about 25 years to 70 years without treatment,
depending on the method of estimation used.10 The IOP
can also have an effect, with higher pressures reducing the
time until blindness.10 There are a range of treatments that
have been shown to be effective in slowing down or haltingthe progress of glaucoma, including the use of medications
such as prostaglandins, or surgical techniques, including laser
surgery. Increased IOP has long been considered to be the
most important risk factor in glaucoma and reduction in
IOP has therefore been the treatment of choice in attempting
to arrest the propagation of optic neuropathy in patients with
glaucoma.11
IOP is normally regulated by changes in the volume of the
aqueous humor. Aqueous humor is continually produced by
the ciliary processes and this rate of production must be
balanced by an equal rate of aqueous humor drainage.
Small variations in the production or outflow of aqueous
humor will have a large influence on the IOP. The probable
mechanism of action of forskolin is through regulation of
aqueous flow by the adenylate cyclase receptor complex in
the ciliary epithelium.11
Sear et al. report the use of forskolin, a potent noradrener-
gic stimulator of adenylate cyclase, have allowed a non-
invasive study in the human eye of the effects of adenylate
cyclase stimulation; i.e., increased cyclic AMP production
upon aqueous humor dynamics. The result of decreased
IOP, decreased inflow, and unchanged outflow facility
supports the idea that the activated ciliary epithelial adeny-
late cyclase receptor complex can reduce net aqueous inflow.
Witte et al. at Hoechst, Germany conducted a pilot double
blind intraindividual comparison of forskolin eye drops
(0.3%–0.6%–1.0%) in 18 healthy male subjects (6 per group)
which demonstrated that forskolin eye drops 0.3%–0.6%–1.0%
lower IOP in healthy male subjects. The reduction in IOP
was between 23% and 28% and the duration of the effect
increased with the concentration from 3 to 5 h.
A randomized, double-blind, placebo–controlled, cross-
over design with forskolin eye drops (1.0% suspension)
revealed a highly significant maximum reduction in 25% in
IOP in 6 h after instillation of forskolin eye drops.12 Another
study conducted in 1986, concurs that two repeated instilla-
tions of 1% forskolin lowered the IOP significantly and
decreased the aqueous flow by 13%, while a single instillation
had no appreciable effect on the IOP.13 In man 50 ll of a
topical suspension of 1% forskolin significantly lowered IOP
in 1 h, the effect reaching a peak at 2 h, remaining significant
for at least 5 h.14
Forskolin and its analogues represent a new class of drugs
active against glaucoma yet differing in molecular mechanism
from that of any previously used drug.15 The prevalence
of complementary and alternative medicine (CAM) use for
glaucoma is approximately 5% and forskolin has been used
successfully as a topical agent to lower IOP.16
In the present study, IOP was measured by a validated
Goldmann applanation tonometry17, as an alternative to the
200 M. Majeed et al.conventional beta blockers and prostaglandin analogues.
Here, forskolin 1% eye drops were found to be significantly
effective in open angle glaucoma by decreasing the aqueous
flow and thereby reduction in IOP.18 Adverse events were of
mild and transient nature. Following this clinical study with
1% w/v, our extensive work on forskolin revealed interesting
facts that forskolin is effective in reducing the IOP even at
lower strengths i.e., at 0.15%.19 Therefore, the product was
not marketed despite having Indian drug regulatory
approval. Currently, randomized, double blind, clinical trial
has been initiated in India with forskolin 0.15%.Conclusion
The results obtained in our trial demonstrate the efficacy
of 1% forskolin (2 drops thrice a day) in achieving fast onset
of action and uniformity of hypotensive activity. Forskolin
1% eye drops were significantly effective in relieving signs
and symptoms of open angle glaucoma. It could be an excel-
lent and safe alternative to currently used treatments espe-
cially considering its natural origin. Also its bronchial
relaxing effect could be a considerable advantage in asth-
matic patients with glaucoma as opposed to beta blockers,
which are contraindicated in such patients. Therefore, forsko-
lin 1% could be recommended as a treatment of choice for
this condition. Further, confirmatory studies on asthmatic
patients having glaucoma are needed on forskolin. Open
labelness is the limitation of the present study.Competing/conflict of interest
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